Inclusion Criteria:

• Patient has one of the selected solid tumors with no distant metastases, and is more than 8 weeks from completion of definitive therapy with intention to cure. Definitive therapies may include various combinations and schedules of surgery, radiotherapy, chemotherapy, and other therapies (e.g., hormonal therapies) delivered alone or as adjuvant/neoadjuvant therapy. In addition, all subjects must show no evidence of progressive disease on routine evaluations prior to enrollment (see exception for prostate carcinoma) Selected Solid Tumors: Stage I to III Non-small cell lung carcinoma (NSCLC); Stage III Breast Cancer; Stage IIB or III Melanoma; Stage II or III Upper GI tract carcinoma (e.g. esophagus, stomach, gallbladder, pancreas); Stage III Colon carcinoma; Stage II, III, or IV (M0 only) Renal cell carcinoma; Stage II, III, or IV (M0 only) Bladder carcinoma; clinically-localized Prostate carcinoma in patients who have completed definitive surgical resection and/or radiation therapy no less than 8 weeks prior to protocol enrollment, but now have a biochemical-only relapse with a rising serum prostate-specific antigen of >0.2 ng/mL after surgery or >1.5 after radiation
• Patient is >=18 years of age on day of signing informed consent
• Patient has an ECOG performance status of 0 or 1
• Patient has adequate organ function as indicated by the following laboratory values:

Absolute Neutrophil count (ANC), >=1,500 /µL Platelets, >=100,000 /µL Hemoglobin, >= 9 g/dL Serum creatinine or calculated creatinine clearance, <=1.5 X institutional upper limit of normal (ULN) OR >=60 mL/min for patients with creatinine levels > 1.5 X institutional ULN (Creatinine clearance should be calculated per institutional standard.) Serum total bilirubin, <= 1.5 X ULN OR Direct bilirubin <= ULN for patients with total bilirubin levels > 1.5 ULN AST (SGOT) and ALT (SGPT), <= 2.5 X ULN Alkaline Phosphatase, <= 2.5 X ULN OR Liver fraction should be <= 2.5 X ULN for patients with unfractionated serum alkaline phosphatase> 2.5 X ULN

Prothrombin time (PT)/Partial thromboplastin time (PTT) OR INR, <=1.2 X ULN Prothrombin time (PT)/Partial thromboplastin time (PTT) <=1.2 X ULN OR INR, <=1.2 X ULN <=1.2 X ULN

• Female patient of childbearing potential has a negative serum pregnancy test within 3 days of study enrollment

Exclusion Criteria:

A patient meeting any of the following criteria is not eligible to participate in this study:

• Patient has been previously treated with any hTERT-containing/targeted vaccine or any prior adenoviral or DNA vaccine
• Patient is currently participating or has participated in a study with an investigational compound or device within 30 days of signing informed consent
• Patient has known hypersensitivity to any component of study vaccine
• Patient has any laboratory value (with the exception of absolute lymphocyte count) at the time of study entry and prior to the first vaccine administration that would be considered Grade 3 or Grade 4 toxicity
• Patient has a history of clinically significant cardiac conditions, including cardiac arrhythmias which have not been controlled within the last 3 months, unstable angina, myocardial infarction (within the last 3 months), or New York Heart Association (NYHA) Class III or IV congestive heart failure. Patient must have no clinically significant ECG abnormalities and not have a pacemaker or cardioverter/defibrillator implanted
• Patient has undergone splenectomy or has any history of autoimmune disorder
• Patient has received immunosuppressive treatment (e.g., substances or treatments known to diminish immune response such as radiation, antimetabolites, alkylators, antilymphocytic sera, systemic corticosteroids) within 1 month prior to enrollment. Topical hydrocortisone up to a concentration of <=1% will be allowed
• Patient has known acquired, inherited, or idiopathic thrombocytopenia, platelet dysfunction or coagulopathy that would contraindicate IM injections. Patient must also have discontinued aspirin, NSAID, or any therapeutic warfarin or low molecular-weight heparin at least 2 weeks prior to enrollment. Patients on prophylactic anticoagulant therapy such as low dose warfarin or heparin flush for in-dwelling catheters, or low dose, cardiac-protective aspirin may be enrolled providing they meet the coagulation entry parameters following discussion with the SPONSOR
• The presence of Coombs positive serology at the time of entry
• Patient has an acute infection requiring intravenous antibiotic, antiviral or antifungal agents within 2 weeks of study entry
• Patient has a history or current evidence of any condition, therapy, or lab abnormality that might confound the results of the study, interfere with the patient's participation for the full duration of the study, or is not in the best interest of the patient to participate
• Patient has known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial
• Patient is, at the time of signing informed consent, a regular user (including "recreational use") of any illicit drugs or had a recent history (within the last year) of drug or alcohol abuse
• Patient is pregnant or breastfeeding, or expecting to conceive at any time during the study or within 1 year after receiving the last vaccination. All patients must agree to contraceptive use/abstinence during the study period and non-menopausal women (women who have experienced menses within the past year) must agree to contraception during the time of study participation and for 1 year following the last vaccination with either V934 or V935
• Patient is known to be Human Immunodeficiency Virus (HIV)-seropositive
• Patient has known history of Hepatitis B or C or active hepatitis A
• Patient has muscle group (deltoid, triceps, or thigh) that cannot be accessed with a 1.27 cm (1/2") needle length
• Patient has been vaccinated for any disease or for prophylaxis within 1 month prior to the first vaccination
• Patient has any metal implants in the area of the injection site (e.g., shoulder implant, in the upper arms or shoulder girdle)
• The patient has been diagnosed with Systemic Lupus Erythematosus (SLE) or has a positive ANA titer and 1 of the following: positive anti-double-stranded DNA antibodies, positive anti-Sm antibodies, or low C3 levels. Patients with a positive ANA screen and/or a positive ANA titer only can be admitted to the trial, if in the opinion of the Investigator, the patient does not meet the American College of Rheumatology (ACR) diagnostic criteria for SLE
• Patient with a history of a prior malignancy with the exception of cervical intraepithelial neoplasia; basal cell carcinoma of the skin; adequately treated localized prostate carcinoma with PSA <1.0; or who has undergone potentially curative therapy with no evidence of that disease for five years, or who is deemed at low risk for recurrence by his/her treating physician